The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (17 analysts) rates it buy, with a mean price target of $104.
Sempra
SRE · a US exchange · USD · Market cap $55.9B · 15,938 employees
Sempra engages in the regulated utilities business in the United States and Mexico.
PASS · Titan Ethical · score 83.7At the last full screen
2026-09-08
Screened 2026-09-08 · the tape above runs as of 08:38 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its distribution label.
Sempra holds its Distribution at $85.47. Consolidating, no directional conviction, held for 282 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 282 days |
| Price at the screen | $85.47 |
| Valuation | 24.77 trailing · 15.44 forward price to earnings |
| Values screen | PASS · score 83.7 |
| Beta | 0.56 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 31.59% | Below 33% | Interest-bearing debt is just 31.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 1.03% | Below 33% | Cash held in interest-bearing accounts and securities is 1.0% of assets, under the one-third limit. | Pass |
| Receivables | 1.62% | Below 49% | Money owed to the company is 1.6% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.43% | Below 5% | Only 1.4% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads AVOID: it trades at roughly a 8% discount to our $92.52 fair value, narrow competitive moat.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 8.2% margin of safety to the base estimate.
Third-party analyst targets: 17 covering, consensus Buy. The average target sits +19% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsSteady utility with little spark to chase
Picture a gas pipe that never bursts yet never widens either. Sempra runs regulated networks across California and Texas, delivering predictable cash but nothing that excites growth investors. Revenue is already shrinking 4 percent, return on equity sits at just 6 percent and the narrow moat offers scant protection if costs keep rising.
At 16.7 times forward earnings the shares trade almost exactly at our fair value with only a 2 percent margin of safety. Analysts may still rate it a buy with a 104 dollar median target, yet the business shows no sign of accelerating profits or widening its edge. Ethical checks clear, but that alone does not create an opportunity.
The real danger lies in higher borrowing costs and tighter state regulation that could squeeze already modest returns. Low growth plus average valuation equals a classic trap for anyone expecting more than slow dividends. Analysis, not advice.
| Forward P/E | 15.4xreasonably valued |
| Trailing P/E | 24.8xa premium valuation |
| EPS, trailing | 3.45 |
| EPS, forward | 5.54 |
| Revenue growth | -0.1%revenue is shrinking |
| Profit margin | 16.8%healthy profit margins |
| Return on equity | 6.7%a modest return on shareholder capital |
| FCF yield | -49.49% |
| Dividend yield | 2.83% |
| Debt to equity | 0.85moderate, manageable leverage |
| Current ratio | 1.64healthy short-term liquidity |
| Beta | 0.56steadier than the market |
| Short interest, float | 0.02% |
| 52-week range | 79.15 - 101.04 |
| Moat | NARROW |
| Market cap | $55.9B |
| Employees | 15,938 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSRE trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (17 analysts) rates it buy, with a mean price target of $104.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (17 analysts) rates it buy, with a mean price target of $104.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Sector Update: Energy Stocks Advance Late Afternoon MT Newswires · 10 Jul 2026
- Sempra (SRE) Reaches Rooftop Solar Milestone As One In Four SDG&E Customers Generate Power Simply Wall St. · 9 Jul 2026
- First U.S. LNG Ships To Asia From Mexico, Avoiding Hormuz Tensions Investor's Business Daily · 9 Jul 2026
- Sempra (SRE) Ships First ECA LNG Cargo As Undervalued Narrative Gains Attention Simply Wall St. · 9 Jul 2026
- Should ECA Phase 1’s First LNG Cargo Shape Sempra’s (SRE) LNG-Led Cash Flow Story? Simply Wall St. · 9 Jul 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-18 | FERRERO PABLO A | Director | 2,600 | $232,778 | |
| 2026-05-14 | DAY DIANA L | Officer | 3,300 | $304,029 | |
| 2026-05-12 | MARK RICHARD J | Director | 1,499 | · | |
| 2026-05-12 | WEAVING ANYA | Director | 1,499 | · | |
| 2026-05-12 | FERRERO PABLO A | Director | 1,499 | · | |
| 2026-05-12 | CONESA ANDRES | Director | 1,499 | · | |
| 2026-04-01 | BIRD JUSTIN CHRISTOPHER | Officer | 1,128 | $109,066 | |
| 2026-03-16 | WOLD DYAN Z. | Officer | 1,539 | $146,790 | |
| 2026-03-12 | KIRK JENNIFER M | Director | 1,000 | $93,440 | |
| 2026-03-11 | WARNER CYNTHIA J | Director | 2,500 | $232,375 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 23 Sept2025 | Julie Johnson | Democrat | sell | 1K–15K |
| 23 Sept2025 | Julie Johnson | Democrat | buy | 1K–15K |
| 23 Sept2025 | Julie Johnson | Democrat | sell | 1K–15K |
| 23 Sept2025 | Julie Johnson | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $92.83 | -2.0% | · | $981 | -2.0% |
| 2 months | $98.82 | -7.9% | · | $921 | -7.9% |
| 3 months | $92.54 | -1.7% | $0.66 | $991 | -0.9% |
| 6 months | $88.35 | +3.0% | $0.66 | $1,038 | +3.8% |
| 1 year | $73.72 | +23.5% | $2.59 | $1,270 | +27.0% |
| 2 years | $70.59 | +28.9% | $5.10 | $1,362 | +36.2% |
| 3 years | $67.15 | +35.6% | $7.50 | $1,467 | +46.7% |
| 5 years | $60.74 | +49.9% | $12.04 | $1,697 | +69.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SRE does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.